首页 > 市场调查报告书 > 製药

眼科药物

市场调查报告书

商品编码

1477254

干眼症市场，依产品类型、依配方类型、依配销通路、地理位置

Dry Eye Disease Market, By Product Type, By Formulation Type, By Distribution Channel, By Geography

出版日期: 2024年04月03日 | 出版商:

Coherent Market Insights | 英文 163 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计2024年干眼症市场价值为73.3亿美元，预计到2031年将达到132.6亿美元，2024年至2031年的年复合成长率(CAGR)为8.8%。

报告范围		报告详情
基准年：	2023年	2024 年市场规模：	73.3 亿美元
历史数据：	2019年至2023年	预测期：	2024年至2031年
预测 2024 年至 2031 年复合年增长率：	8.80%	2031 年价值预测：	132.6 亿美元

图 1. 干眼症市场占有率 (%)，依地区划分，2024 年

干眼症，也称为干燥性角结膜炎，是一种泪液和眼表的多因素疾病，会导致不适、视力障碍和泪膜不稳定的症状，并对眼睑间眼表造成潜在损害。它伴随着泪膜渗透压的增加和眼表的发炎。由于人口老化和数位设备的更多使用，干眼症在全球范围内成为一个日益严重的问题，导致眨眼频率降低和睁眼时间增加。儘管干眼症通常被认为是一种轻微的、令人讨厌的疾病，但它会对生活品质和生产力产生负面影响。

市场动态：

全球干眼症市场是由全球老年人口不断增长所推动的，老年人口主要因年龄相关的泪液产生减少而受到干眼症的影响。此外，长时间使用智慧型手机、笔记型电脑和平板电脑等数位设备会导致眼睛疲劳，导致干眼症，进而推动市场成长。然而，对干眼症的治疗选择、自我保健和管理缺乏认识，尤其是在发展中国家，这是主要的市场限制。市场参与者有机会探索产品开发的新途径，包括创新的人工泪液输送方法和旨在解决干眼症症状和体征的联合疗法。

研究的主要特点：

该报告对全球干眼症市场进行了深入分析，并提供了以2023年为基准年的预测期（2024-2031年）的市场规模（十亿美元）和年复合成长率（CAGR%）。
它阐明了不同细分市场的潜在收入成长机会，并解释了该市场有吸引力的投资主张矩阵。
这项研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采取的竞争策略的重要见解。
它根据以下参数描述了全球干眼症市场的主要参与者——公司亮点、产品组合、主要亮点、财务表现和策略。
该报告的见解将使行销人员和公司管理当局能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
全球干眼症市场报告迎合了该行业的各个利益相关者，包括投资者、供应商、产品製造商、分销商、新进业者和财务分析师。
利害关係人可以透过用于分析全球干眼症市场的各种策略矩阵轻鬆做出决策。

介绍
北美洲
我们
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
拉丁美洲其他地区
欧洲
英国
德国
义大利
法国
西班牙
俄罗斯
欧洲其他地区
亚太地区
中国
印度
日本
东协
澳洲
韩国
亚太地区其他地区
中东
海湾合作委员会
以色列
中东其他地区
非洲
北非
中非
南非

第 9 章：竞争格局

公司简介
- Novartis AG
- Alcon Inc.
- I-MED Pharma Inc
- Sun Pharmaceutical Industries Ltd.
- Novaliq GmbH
- Cipla Inc.
- AbbVie Inc.
- Lupin
- Otsuka Holdings Co., Ltd.
- Santen Pharmaceutical Co., Ltd
- Cambium Medical Technologies
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd.
- Bausch & Lomb Incorporated
- Abbott
- Adrif Vision
- Grevis Pharmaceuticals Pvt. Ltd.
- AFT Pharmaceuticals
- URSAPHARM Arzneimittel GmbH
- Altacor

第 10 章：分析师观点

命运之轮
分析师观点
连贯的机会图

第 11 章：参考文献与研究方法

参考
研究方法论

简介目录

Product Code: CMI5438

The dry eye disease market is estimated to be valued at USD 7.33 Bn in 2024 and is expected to reach USD 13.26 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.8% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 7.33 Bn
Historical Data for:	2019 To 2023	Forecast Period:	2024 To 2031
Forecast Period 2024 to 2031 CAGR:	8.80%	2031 Value Projection:	US$ 13.26 Bn

Figure 1.Dry Eye Disease Market, Share (%), By Region, 2024

Dry eye disease, also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the interpalpebral ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface. Dry eye disease is a growing problem worldwide due to aging populations and greater use of digital devices, leading to decreased blink rates and more time spent with eyes open. Although often thought of as a mild, nuisance disease, dry eye can negatively impact quality of life and productivity.

Market Dynamics:

The global dry eye disease market is driven by the rising geriatric population globally which is majorly affected by dry eye disease due to age-related decreasing tear production. Furthermore, increasing usage of digital devices, such as smartphones, laptops, and tablets, for extended periods are majorly straining eyes leading to dry eyes, thereby driving the market growth. However, lack of awareness about treatment options, self-care, and management of dry eye disease especially in developing nations act as major market restraints. Market participants have the chance to explore new avenues in product development, including innovative delivery methods for artificial tears and combination therapies aimed at addressing both the signs and symptoms of dry eye disease.

Key Features of the Study:

This report provides an in-depth analysis of the global dry eye disease market, and provides market size (USD BN) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global dry eye disease market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study includes Novartis AG, Alcon Inc., I-MED Pharma Inc, Sun Pharmaceutical Industries Ltd., Novaliq GmbH, Cipla Inc., AbbVie Inc., Lupin, Otsuka Holdings Co., Ltd., Santen Pharmaceutical Co., Ltd, Cambium Medical Technologies, Viatris Inc., Teva Pharmaceutical Industries Ltd., Bausch & Lomb Incorporated, Abbott, Adrif Vision, Grevis Pharmaceuticals Pvt. Ltd., AFT Pharmaceuticals, URSAPHARM Arzneimittel GmbH, and Altacor.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global dry eye disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dry eye disease market.

Detailed Segmentation-

Product Type:
- Cyclosporine
- Corticosteroids
- Lifitegrast
- Ocular Lubricant
- Punctal Plugs
- Others
Formulation Type:
- Liquid
- Gel
- Ointment
- Others
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Supermarket/Hypermarket
- Other Stores
- Online Pharmacies
Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Novartis AG
- Alcon Inc.
- I-MED Pharma Inc
- Sun Pharmaceutical Industries Ltd.
- Novaliq GmbH
- Cipla Inc.
- AbbVie Inc.
- Lupin
- Otsuka Holdings Co., Ltd.
- Santen Pharmaceutical Co., Ltd
- Cambium Medical Technologies
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd.
- Bausch & Lomb Incorporated
- Abbott
- Adrif Vision
- Grevis Pharmaceuticals Pvt. Ltd.
- AFT Pharmaceuticals
- URSAPHARM Arzneimittel GmbH
- Altacor

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Formulation Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Recent Developments
Acquisitions and Partnerships Scenario
Technology Overview
Regulatory Scenario
Pricing Analysis
PEST Analysis

4. Global Dry Eye Disease Market - Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 impact on the market

5. Global Dry Eye Disease Market, By Product Type, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Cyclosporine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Corticosteroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Lifitegrast
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Ocular Lubricant
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Punctal Plugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

6. Global Dry Eye Disease Market, By Formulation Type, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Liquid
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Gel
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Ointment
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

7. Global Dry Eye Disease Market, By Distribution Channel, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Supermarket/Hypermarket
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Other Stores
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

8. Global Dry Eye Disease Market, By Region, 2019 - 2031, (USD BN)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Regions, 2019-2031
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Formulation Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Formulation Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Formulation Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Formulation Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Formulation Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Formulation Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD BN)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Company Profiles
- Novartis AG
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
- Alcon Inc.
- I-MED Pharma Inc
- Sun Pharmaceutical Industries Ltd.
- Novaliq GmbH
- Cipla Inc.
- AbbVie Inc.
- Lupin
- Otsuka Holdings Co., Ltd.
- Santen Pharmaceutical Co., Ltd
- Cambium Medical Technologies
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd.
- Bausch & Lomb Incorporated
- Abbott
- Adrif Vision
- Grevis Pharmaceuticals Pvt. Ltd.
- AFT Pharmaceuticals
- URSAPHARM Arzneimittel GmbH
- Altacor